Provectus Biopharmaceuticals Files 8-K on Security Holder Vote

TL;DR

Provectus Biopharma is having a shareholder vote, details to follow.

AI Summary

On June 20, 2024, Provectus Biopharmaceuticals, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The filing does not contain specific details on the nature of the vote or any associated financial figures.

Why It Matters

This filing indicates that Provectus Biopharmaceuticals is seeking approval from its security holders on certain matters, which could impact corporate governance or future strategic decisions.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose any immediate financial risks or significant operational changes.

Key Players & Entities

• PROVECTUS BIOPHARMACEUTICALS, INC. (company) — Registrant
• June 20, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 800 S. Gay Street , Suite 1610 , Knoxville , TN 37929 (address) — Principal business address

FAQ

Filing Documents

• form8-k.htm (8-K) — 53KB
• 0001493152-24-024661.txt ( ) — 219KB
• pvct-20240620.xsd (EX-101.SCH) — 3KB
• pvct-20240620_lab.xml (EX-101.LAB) — 33KB
• pvct-20240620_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 3KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 800 S. Gay Street , Suite 1610 , Knoxville , TN 37929 (Address of Principal Executive Offices) (Zip Code) (866) 594-5999 (Registrant's Telephone Number, Including Area Code) N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: None Title of each class Trading Symbol(s) Name of each exchange on which registered Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.07. Submission of Matters to a Vote of Security Holders. Provectus Biopharmaceuticals, Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting") on June 20, 2024. At the Annual Meeting, the Company's stockholders voted on six proposals. A brief description and tabulation of votes for each proposal are set forth below. Proposal 1 . The Company's stockholders elected the following directors for a term of one-year, consistent with the recommendation of the Company's board of directors (the "Board"). There were 115,046,892 broker non-votes with respect to the proposal. Name of Candidate Number of Votes For Withhold Authority Webster Bailey 205,949,353 6,507,886 John Lacey, III, M.D. 205,184,898 7,272,341 Ed Pershing, CPA 206,582,548 5,874,691 Dominic Rodrigues 204,470,934 7,986,305 Proposal 2 . The Company's stockholders approved the advisory vote on the compensation of the Company's named executive officers, consistent with the Board's recommendation. There were 115,046,8892 broker non-votes with respect to the proposal. Number of Votes For 202,805,082 Against 7,101,163 Abstention 2,550,994 Proposal 3 . The Company's stockholders ratified the selection of Marcum LLP as the Company's independent registered public accounting firm for 2024, consistent with the Board's recommendation. There were no broker non-votes with respect to the proposal. Number of Votes For 325,749,039 Against 1,056,266 Abstention 698,826 Proposal 4 . The Company's stockholders authorized the Board to amend the Company's Certificate of Incorporation, as amended by the Certificate of Designation of Series D Convertible Preferred Stock and Certificate of Designation of Series D-1 Convertible Preferred Stock (the "Certificates of Designation"), to effect a reverse stock split of the Company's common stock, Series D Convertible Preferred Stock, and Series D-1 Convertible Preferred Stock at a ratio of between 1-for-10 and 1-for-50, where the ratio would be determined by the Board at its discretion, and to make corresponding amendments to the Certificates of Designation to provide for the proportional adjustment of certain terms upon a reverse stock split, consistent with the Board's recommendation. There were no broker non-votes with respect to the proposal. Number of Votes For 302,863,077 Against 21,501,015 Abstention 3,140,039 Proposal 5 . The Company's stockholders authorized the Board, given the Company's stockholders' approval of Proposal 5, to amend the Company's Certificate of Incorporation, as amended by the Certificates of Designation, to decrease the number of authorized shares of the Company's common stock and preferred stock by the same reverse stock split ratio determined by the Board, consistent with the Board's recommendation. There were no broker non-votes with respect to the proposal. Number of Votes For 303,149,090 Against 21,258,881 Abstention 3,09

View Full Filing

View this 8-K filing on SEC EDGAR